Metabolon CEO Named One of the Most Inspiring People in Life Sciences
PharmaVOICE magazine recognizes Dr. John Ryals for his contributions to the industry.
RESEARCH TRIANGLE PARK, NC (August 30, 2005) – Metabolon, Inc., a leader in the discovery of biomarkers through the use of metabolomics, today announced its president and CEO, Dr. John Ryals, has been selected as one of the â€œ100 Most Inspiring People in the Life Sciences Industryâ€ by the readers of PharmaVOICE magazine. Dr. Ryals is showcased in the magazineâ€™s August issue.
â€œI am honored to be recognized as an inspiring member of the life sciences community,â€ said Dr. Ryals. â€œBut this would have never been possible without all of the incredible people Iâ€™ve worked with over the years.â€
Individuals were selected based on how they have inspired and motivated those around them, their influence as a corporate leader, and how they have had a positive impact on the industry through their actions.
By educating the public on metabolomics, its benefits and importance, Dr. Ryals has quickly established Metabolon at the forefront of the biomarker industry. With more than 20 years of experience in biotechnology, Dr. Ryals brings a balance of entrepreneurial expertise and a deep background in life sciences to the company helm.
Dr. Ryals currently serves on the Life Science Advisory Board of The Aurora Funds, the Board of Directors at Athenix Corporation and the Board of Directors for the North Carolina State University Physical and Mathematical Sciences Foundation. Dr. Ryals is also internationally known for his scientific work and has been recognized as a Highly Cited Author in Plant and Animal Science, ranked number one for the United States and number four in the world for papers published and cited in ISI-indexed journals of plant and animal science between 1992 and 2002.
Metabolon is an industry leader in the discovery of biomarkers through the use of metabolomics, a powerful and new scientific approach for the discovery and development of drugs and the early diagnosis of disease states. Metabolon's patent-pending technology is poised to dramatically impact drug discovery and development processes by accurately measuring the spectrum of biochemical changes and mapping these changes to metabolic pathways. Metabolon's technology can identify safer compounds for development, shorten the time for drugs to get to market and identify novel biomarkers for earlier disease detection. In conjunction with the NIH, Metabolon was recently honored as a recipient of the 2005 March of Dimes Award for Best Research in Prematurity. For additional information, visit www.metabolon.com.
For more information: